Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 4/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21820325 | 1.00 | SNCA (0.54) | SNCAGPR119MAPTLMNAALDH1A1 | |
| SCHEMBL21751996 | 0.89 | SNCA (0.58) | SNCAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL21752128 | 0.87 | GPR119 (0.48) | SNCAGPR119MAPTLMNAALDH1A1 | |
| SCHEMBL26017758 | 0.87 | GPR119 (0.48) | SNCAGPR119MAPTLMNAALDH1A1 | |
| SCHEMBL28577452 | 0.82 | SNCA (0.45) | SNCAGPR119MAPTLMNAALDH1A1 | |
| SCHEMBL21771119 | 0.79 | SNCA (0.71) | SNCAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL28570456 | 0.78 | SNCA (0.46) | SNCAGPR119MAPTLMNAALDH1A1 | |
| SCHEMBL21751950 | 0.76 | SNCA (0.60) | SNCAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL26017855 | 0.76 | SNCA (0.60) | SNCAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL26037891 | 0.76 | SNCA (0.60) | SNCAMAPTLMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | SNCA 8/4885GPR119 3718/4885MAPT 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.